1.43
-0.18(-11.18%)
Currency In USD
| Previous Close | 1.61 |
| Open | 1.6 |
| Day High | 1.6 |
| Day Low | 1.42 |
| 52-Week High | 187.44 |
| 52-Week Low | 1.4 |
| Volume | 293,158 |
| Average Volume | 729,808 |
| Market Cap | 3.2M |
| PE | -0.08 |
| EPS | -17.2 |
| Moving Average 50 Days | 3.9 |
| Moving Average 200 Days | 10.61 |
| Change | -0.18 |
If you invested $1000 in Vincerx Pharma, Inc. (VINC) since IPO date, it would be worth $7.65 as of February 05, 2025 at a share price of $1.43. Whereas If you bought $1000 worth of Vincerx Pharma, Inc. (VINC) shares 3 years ago, it would be worth $10.3 as of February 05, 2025 at a share price of $1.43.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Vincerx Pharma, Inc. and Oqory, Inc. Highlight Promising Data for Oqory’s TROP2 Antibody Drug Conjugate, OQY-3258
GlobeNewswire Inc.
Jan 29, 2025 1:00 PM GMT
Companies also provide insights into proposed strategic mergerSAN MATEO, Calif., Jan. 29, 2025 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (Nasdaq: VINC), a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer
Vincerx Pharma, Inc. Announces Reverse Stock Split
GlobeNewswire Inc.
Jan 23, 2025 9:05 PM GMT
Vincerx’s Common Stock to Begin Trading on a Split-adjusted Basis on January 28, 2025SAN MATEO, Calif., Jan. 23, 2025 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (Nasdaq: VINC), a biopharmaceutical company aspiring to address the unmet medical needs o
Vincerx Pharma Enters into a Binding Term Sheet for a Strategic Merger with Oqory, Inc.
GlobeNewswire Inc.
Dec 27, 2024 9:05 PM GMT
Proposed merger would add a differentiated Phase 3 TROP2 Antibody-drug Conjugate (ADC) to the combined company’s pipelinePALO ALTO, Calif., Dec. 27, 2024 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (Nasdaq: VINC), a biopharmaceutical company aspiring